Symptoms are common in dementia at the end of life, despite the large majority of residents receiving opioids. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Research
29,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
The two major neurodegenerative diseases Alzheimer's disease (AD) and Parkinson's disease (PD) are characterised by low levels in the brain of the neurotransmitters acetylcholine (ACh) and dopamine (DA), respectively. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Feeding and eating difficulties leading to weight loss are common in the advanced stages of dementia. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
36/100
In 2009, nearly 66 million Americans (three in 10 U.S. households) reported at least one person providing unpaid care as a family caregiver. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Current palliative treatments are attempts to minimize the morbidity of abnormal behaviors and medical complications associated with dementia. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
If the ulcer has become chronic, the ultimate goal changes from healing the wound to controlling symptoms (such as foul odour, pain, discomfort and infection) and preventing complications, thereby contributing to the patient's overall well-being; providing support for the patient's family is also important. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Inhibition of phosphodiesterase 9 (PDE9) has been reported to enhance rodent cognitive function and may represent a potential novel approach to improving cognitive dysfunction in Alzheimer's disease. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Older adults with dementia commonly have multiple chronic conditions that prompt clinicians to prescribe medications. 5 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source
Neurodegenerative diseases remain a huge unmet pharmaceutical need. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The number of people with dementia is increasing rapidly worldwide. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Although physicians, nurses and relatives are all guided by the best interest of the patient, it seems that differences in religious beliefs, perspective of the patient, and responsibility can lead to different attitudes towards end-of-life decisions. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and many others represent a relevant health problem with age worldwide. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
ACP does not seem to have a systematic place in the care for all community-dwelling older people. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The age-adjusted death rate decreased from 747.0 deaths per 100,000 population in 2010 to 740.6 deaths per 100,000 population in 2011. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
As the US elderly population continues to expand rapidly, Alzheimer's disease poses a major and increasing public health challenge, and older African Americans may be disproportionately burdened by the disease. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The vitamins folic acid, B12 and B6 and B2 are the source of coenzymes which participate in one carbon metabolism. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer disease is the most common cause of dementia. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Experimental studies have shown that stress can significantly alter the effects of Pb, effects that could potentially be mediated through alterations in the interactions of glucocorticoids with the mesocorticolimbic dopamine system of the brain. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The age-adjusted death rate decreased from 758.7 deaths per 100,000 population in 2008 to 741.0 deaths per 100,000 population in 2009. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The insulin resistance syndrome (syndrome X, metabolic syndrome) has become the major health problem of our times. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
In 2010, the 10 leading causes of death were, in rank order: Diseases of heart; Malignant neoplasms; Chronic lower respiratory diseases; Cerebrovascular diseases; Accidents (unintentional injuries); Alzheimer's disease; Diabetes mellitus; Nephritis, nephrotic syndrome and nephrosis; Influenza and pneumonia; and Intentional self-harm (suicide). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The use of turmeric, derived from the root of the plant Curcuma longa, for treatment of different inflammatory diseases has been described in Ayurveda and in traditional Chinese medicine for thousands of years. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Finally, the exposome concept is new in the biomarker discovery arena and it is suggested as a way to move forward in identifying biomarkers of neurological diseases. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Disorders of the central nervous system (CNS) are some of the most prevalent, devastating and yet poorly treated illnesses. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
This paper summarises a literature review focusing on the literature directly pertaining to the acute care of older people with dementia in general hospitals from 2007 onwards. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 29,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 29,780 records, built mostly from automated pulls of Europe PMC (63.8% of the library) and OpenAlex (17.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,037 records (3.5% of the library) are not peer-reviewed — 964 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →